Welcome to our dedicated page for YD Bio news (Ticker: YDES), a resource for investors and traders seeking the latest updates and insights on YD Bio stock.
YD Bio Limited (NASDAQ: YDES) is a biotechnology company that regularly issues news on DNA methylation‑based cancer detection, precision diagnostics, ophthalmologic innovations, and stem cell and exosome therapies. Its press releases describe progress across oncology diagnostics, limbal stem cell–derived exosome platforms, and clinical‑trial supply operations, giving investors and observers insight into how the company is advancing its programs.
News updates for YD Bio often cover developments in its collaboration with EG BioMed, including expansion of the OkaiDx™ cfDNA‑methylation blood‑based testing platform for cancers such as pancreatic, colorectal, and breast cancer. Announcements have detailed CLIA and CAP accreditation for EG BioMed’s U.S. laboratory, expanded state‑by‑state access to laboratory‑developed tests, and clinical research data for early pancreatic cancer detection assays that remain under validation and are not yet FDA‑cleared or approved.
Another recurring theme in YD Bio’s news is ophthalmology. Releases describe milestones in limbal stem cell and exosome‑based platforms, FDA 510(k) clearance for Exovisse contact lenses, over‑the‑counter monograph compliance for Exovisse artificial tears, and planned clinical programs for eye conditions. The company also reports on regulatory filings such as Drug Master Files for limbal stem cells and exosomes, as well as planned clinical studies in Taiwan and regulatory strategies in the United States.
Corporate and capital markets developments appear in YD Bio’s news flow as well, including the closing of its business combination with Breeze Holdings Acquisition Corp., listing on the Nasdaq Global Market, and a non‑binding Memorandum of Understanding to merge with EG BioMed. Readers following YDES news can expect coverage of scientific presentations, intellectual property updates, facility plans such as a proposed California operations center, and governance or auditor changes disclosed through SEC reports and press releases.
YD Bio (NasdaqGM: YDES) announced support for U.S. access to OkaiDx™, a cfDNA‑methylation blood test for post‑treatment breast cancer monitoring, now available through affiliate EG BioMed’s CLIA/CAP‑certified laboratory as a research‑use‑only (RUO) assay.
The company will coordinate commercialization, researcher engagement and sample logistics to enable testing for research laboratories, academic groups and industry partners. Independent validation reported 95.1% accuracy, 89.4% sensitivity and 96.5% specificity. OkaiDx™ is not FDA cleared and is not intended to diagnose, treat, cure or prevent disease.
YD Bio (Nasdaq: YDES) rang the Nasdaq Opening Bell on October 20, 2025 to mark its listing on the Nasdaq Global Market. The company said the listing strengthens its capital base, elevates its global profile and accelerates commercialization of DNA methylation cancer-detection tests and exosome-based ophthalmologic therapies.
YD Bio highlighted exclusive 20-year licenses from EG Biomed and 3D Global Biotech, plans to expand R&D and a Seattle-based CLIA and CAP certified laboratory, and indicated the listing will support product launches and long-term value for patients and investors.
YD Bio (Nasdaq: YDES) announced that its business partner EG BioMed achieved CAP accreditation for its CLIA-certified laboratory in Bothell, Washington (CLIA Certificate #50D2316600) on October 10, 2025. CAP accreditation, alongside existing CLIA certification, confirms laboratory quality standards and strengthens EG BioMed’s ability to deliver advanced laboratory-developed tests (LDTs) supporting YD Bio’s DNA methylation-based pancreatic and breast cancer detection programs in the U.S.
YD Bio highlighted that this accreditation positions the companies to expand their diagnostic portfolio for early cancer detection and monitoring. EG BioMed’s Chief R&D Officer presented new circulating cell-free DNA biomarker findings at AACR (September 28–October 1, 2025) relevant to metastatic pancreatic cancer monitoring.
YD Bio Limited (NASDAQ:YDES) reported its H1 2025 financial results, marked by strategic developments despite financial headwinds. The company's net revenue decreased 9% to $204,007, while operating expenses increased significantly to $2.0 million, resulting in a net loss of $1.9 million.
Key developments include securing $13.2 million in PIPE financing through a business combination with Breeze Holdings, advancing DNA methylation-based cancer detection technology, and expanding into ophthalmologic innovations. The company launched a pancreatic cancer screening LDT and plans to introduce a breast cancer recurrence monitoring LDT. Additionally, YD Bio is developing corneal stem-cell and exosome-based treatments for various eye conditions, with clinical trials planned for 2027.
YD Bio Limited (NASDAQ: YDES) has successfully completed its business combination with Breeze Holdings Acquisition Corp and commenced trading on the Nasdaq Global Market. The transaction, approved on August 14, 2025, includes a PIPE offering that, combined with trust funds, will provide over $11.5 million for future operations.
Led by Chairman Dr. Ethan Shen, YD Bio focuses on three core areas: DNA methylation-based cancer detection through partnership with EG BioMed, ophthalmology therapies developed with 3D Global Biotech, and clinical trial support services. The company's cancer detection portfolio includes a pancreatic cancer screening test and an upcoming breast cancer recurrence monitoring test, while their ophthalmology program plans to initiate trials for exosome-based treatments in 2027.
YD Bio Limited (NASDAQ: YDES) has successfully completed its business combination with Breeze Holdings Acquisition Corp and will begin trading on the Nasdaq Global Market on August 29, 2025. The company secured over $11.5 million in funding through a PIPE offering and trust proceeds.
Led by Chairman Dr. Ethan Shen, YD Bio focuses on three core areas: DNA methylation-based cancer detection technology, stem cell and exosome-based ophthalmology therapies, and clinical trial support services. Key developments include a pancreatic cancer screening test available as an LDT, an upcoming breast cancer monitoring test, and planned trials for exosome-based ophthalmic treatments in 2027.